Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 618

Results For "ED"

9532 News Found

USFDA approves Injectafer for the treatment of iron deficiency in adult patients with heart failure
Drug Approval | June 06, 2023

USFDA approves Injectafer for the treatment of iron deficiency in adult patients with heart failure

Injectafer is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency


Briefs: Ipca Laboratories, Lupin and Zydus
News | June 05, 2023

Briefs: Ipca Laboratories, Lupin and Zydus

The company has extended its full co-operation and support to the officials of the Income Tax Department


OMRON Healthcare to launch operations in March 2025 at Origins by Mahindra in Chennai
Medical Device | June 05, 2023

OMRON Healthcare to launch operations in March 2025 at Origins by Mahindra in Chennai

The OMRON Healthcare factory will be built over 6.02 acres and will be manufacturing blood pressure monitors and supplying them mainly to the domestic market.


International cooperation must to advance vaccine development for emerging pathogens: Health Minister Mandaviya
Policy | June 04, 2023

International cooperation must to advance vaccine development for emerging pathogens: Health Minister Mandaviya

The development and deployment of effective vaccines can help to mitigate the impact of pandemics, and we must prioritize research efforts to achieve this objective


Innovent announces 2nd BTD by NMPA for Olverembatinib for treatment of patients with SDH-deficient GIST
Biotech | June 03, 2023

Innovent announces 2nd BTD by NMPA for Olverembatinib for treatment of patients with SDH-deficient GIST

Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors


Novartis receives European approval for Cosentyx
Drug Approval | June 03, 2023

Novartis receives European approval for Cosentyx

European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5


Sun Pharma and Philogen enter into an agreement for commercializing NIDLEGY
News | June 03, 2023

Sun Pharma and Philogen enter into an agreement for commercializing NIDLEGY

Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe


3M to invest nearly $150 million on expanding biopharma filtration capabilities
News | June 03, 2023

3M to invest nearly $150 million on expanding biopharma filtration capabilities

The investment will include facility and equipment improvements and the addition of 60 full-time positions in 3M manufacturing facilities in Europe.


AstraZeneca receives CDSCO approval for Tremelimumab combination in India
Drug Approval | June 02, 2023

AstraZeneca receives CDSCO approval for Tremelimumab combination in India

Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)


Pfizer’s phase 3 studies of novel antibiotic combination offer new hope for patients with multidrug-resistant infections and treatment options
Clinical Trials | June 02, 2023

Pfizer’s phase 3 studies of novel antibiotic combination offer new hope for patients with multidrug-resistant infections and treatment options

Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone